George Bakris to Endothelin A Receptor Antagonists
This is a "connection" page, showing publications George Bakris has written about Endothelin A Receptor Antagonists.
Connection Strength
0.521
-
Atrasentan and renal events in patients with type 2 diabetes and chronic kidney disease (SONAR): a double-blind, randomised, placebo-controlled trial. Lancet. 2019 05 11; 393(10184):1937-1947.
Score: 0.174
-
Baseline characteristics and enrichment results from the SONAR trial. Diabetes Obes Metab. 2018 08; 20(8):1829-1835.
Score: 0.163
-
Rationale and protocol of the Study Of diabetic Nephropathy with AtRasentan (SONAR) trial: A clinical trial design novel to diabetic nephropathy. Diabetes Obes Metab. 2018 06; 20(6):1369-1376.
Score: 0.161
-
A selective endothelin-receptor antagonist to reduce blood pressure in patients with treatment-resistant hypertension: a randomised, double-blind, placebo-controlled trial. Lancet. 2009 Oct 24; 374(9699):1423-31.
Score: 0.022